[ET Net News Agency, 26 April 2023] HSBC Global Research lowered its target price for
Sino Biopharm (01177) to HK$6.3 from HK$6.5 and maintained its "buy" rating.
The research house said it lowers 2023-24e revenue estimates by 5%/8% mainly due to
capacity issues for PD-1 and the impact of the 8th round of Volume-Based Procurement (VBP)
on Calcitriol. (RC)